Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Kite, A Gilead Company.

Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies


Release Date: June 29, 2018
Expiration Date: June 29, 2019
Media: Internet - based
 

Activity Overview

PER Global®, LLC, the global affiliate of Physicians’ Education Resource®, LLC, (PER®) is pleased to present the CME-certified online activity titled Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies. This innovative activity is an archived version of the live-streamed interactive webcast held on May 24, 2018, and led by international hematologic malignancies experts Paolo Ghia, MD, PhD, Krishna V. Komanduri, MD, and Jae H. Park, MD.  Our experts will bring you key insights into the clinical application of chimeric antigen receptor T-cell (CAR-T) therapy.  For patients with leukemia or lymphoma, stem cell transplantation (SCT) provides the best chance for long-term remission; however, not all patients are eligible, and patients who relapse after SCT have a poor prognosis. This has led to the development of therapies with nonoverlapping mechanisms of action, such as CAR T cells.
 
This exciting online activity offers education to augment your foundation of knowledge and clinical competence in several areas, including:
  • The unique mechanism of action of CAR T cells
  • Clinical considerations for the use of CAR T cells, and differentiation from chemotherapy and targeted therapy
  • Data demonstrating durable complete responses in patients with heavily pretreated B-cell acute lymphoblastic leukemia or aggressive B-cell lymphoma
  • Managing adverse events associated with CAR T cells 
Join us online for Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies, which will bring medical conference‒caliber education to the convenience of your screen!

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Kite, A Gilead Company.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed towards ex-US clinicians, including medical oncologists, hematologists, nurses, and fellows who treat patients with hematologic malignancies. Physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies are also invited to participate.

Learning Objectives

Upon completion of this activity, you should be better prepared to:

  • Explain the mechanism of action of CAR T cells in hematologic malignancies, and differentiate between available and emerging therapies
  • Describe the manufacture of CAR T cells and the standards under which manufacturing is conducted
  • Discuss recent clinical trial data concerning the application of CAR T-cell strategies in the context of evolving treatment paradigms for hematologic malignancy management
  • Delineate appropriate techniques to identify and manage different treatment-related toxicities in the care of patients who receive CAR T-cell therapies
Moderator

Paolo Ghia, MD, PhD
Università Vita-Salute San Raffaele
Director, Strategic Research Program on CLL
IRCCS San Raffaele Scientific Institute
Milan, Italy
 

DisclosuresGrant/Research Support: AbbVie, Janssen, Gilead; Consultant: AbbVie, Acerta, BeiGene, Janssen, Pharmacyclics, Gilead; Speakers’ Bureau: Gilead

Faculty

Krishna V. Komanduri, MD
Kalish Family Chair in Stem Cell Transplantation
Professor of Medicine, Microbiology & Immunology
Director, Adult Stem Cell Transplant Program
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL

DisclosuresAd Hoc Advisor: Kite, Novartis, Juno; Co-Investigator: Kite, Novartis, Adaptimmune, Juno

Jae H. Park, MD
Assistant Attending Physician
Department of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
 

DisclosuresConsultant: Amgen, Novartis, Adaptive Biotechnologies

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that creates a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the company that provided commercial support for this activity.

 







Become a Member

Forgot Password?
Filter By